ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Basel biotech 201 Therapeutics receives CHF150K from Venture Kick on 16/11/2026 to optimize liver cancer drug candidates. CEO Sandro Nuciforo leads the team developing small-molecule therapies targeting liver cells using patient-derived tumor models.
Tap to vote and see what everyone thinks.
Summary by ByteBrief